Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
The London Company Small Cap The London Company of Virginia, LLC | “CERT was a bottom performer as the stock sold off on softer top line and bookings results, despite improving profitability and higher EPS guidance. While organic software growth has fallen short of expectations, margins, cash flow, and software mix continue to trend positively. We continue to like CERT for its dominant market position, low capital intensity, strong cash flow generation, and a long-term growth opportunity as computer simulation adoption expands over traditional methods. BSD Analysis: Certara sells decision-critical software embedded deep in drug development workflows where mistakes are expensive and reputations are permanent. Regulators increasingly expect quantitative modeling, which turns Certara into infrastructure rather than optional tooling. Biotech funding cycles pressure growth optics, not customer dependence. Switching costs are intellectual and regulatory, not contractual, which is stronger than it looks on paper. Investors confuse slower bookings with competitive loss. Software margins expand as services become a smaller mix over time. Expansion comes from deeper penetration, not logo chasing. This is life sciences plumbing compounding behind the scenes.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Meridian Small Cap Growth Fund Chad Meade | “Certara, Inc. develops software and services that support drug development through biosimulation, modeling how investigational compounds interact at varied dosing levels with organs and other drugs. A large majority of recent FDA-approved drugs used a Certara solution during development. During the quarter, the stock underperformed due to weaker-than-expected service bookings, which led management to slightly lower guidance. The appointment of a new CEO has shifted the company toward a more commercially focused strategy. Additionally, the potential divestiture of a non-core, lower-moat business could simplify the story and improve growth focus. BSD Analysis: Certara sells decision-critical software embedded in drug development workflows where mistakes are expensive and reputations are permanent. Regulators increasingly expect quantitative modeling, which quietly entrenches Certara as infrastructure rather than optional tooling. Biotech funding cycles pressure growth optics, not customer dependence. Switching costs are intellectual and regulatory, not contractual, which is stronger than it looks on paper. Investors confuse slower bookings with competitive loss. Software margins scale as services become a smaller mix over time. Expansion comes from deeper penetration into existing accounts, not logo chasing. This is life sciences infrastructure compounding behind the scenes while sentiment chases shinier biotech stories.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Meridian Growth Fund ArrowMark Colorado Holdings, LLC | “Certara, Inc. develops software and services that support drug development through biosimulation, modeling how investigational compounds interact at varied dosing levels with organs and other drugs. While the technology remains relatively early in adoption, a large majority of recent FDA-approved drugs used a Certara solution at some point in the development process. During the quarter, the company underperformed due to weaker-than-expected service bookings, which prompted management to slightly lower guidance. However, with the recent appointment of a new CEO who is adopting a more commercially focused strategy, as well as the potential divestiture of a non-core, lower-moat business segment, Certara is positioned to transform into a more focused, pure-play growth company. BSD Analysis: Certara sells decision-critical software and services embedded in drug development workflows where mistakes are expensive. Regulatory complexity and modeling requirements create real switching costs. Biotech funding cycles pressure growth optics, not relevance. The platform benefits as regulators increasingly expect quantitative modeling. Investors confuse slower bookings with competitive loss. High-margin software offsets lower-margin services over time. Expansion comes from deeper customer penetration, not logo chasing. This is life sciences infrastructure quietly compounding behind the scenes.” | BEAR | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
